Synthetic Biologics Inc (NYSEMKT:SYN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. “
Separately, ValuEngine raised shares of Synthetic Biologics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $3.92.
Synthetic Biologics (SYN) opened at 0.90 on Tuesday. The stock’s 50 day moving average is $0.84 and its 200-day moving average is $0.63. The company’s market cap is $115.42 million. Synthetic Biologics has a 12-month low of $0.41 and a 12-month high of $1.68.
Synthetic Biologics (NYSEMKT:SYN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. Analysts predict that Synthetic Biologics will post ($0.17) earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Creative Planning increased its position in Synthetic Biologics by 65.4% during the second quarter. Creative Planning now owns 177,000 shares of the company’s stock worth $100,000 after acquiring an additional 70,000 shares during the period. Susquehanna International Group LLP increased its position in Synthetic Biologics by 76.4% during the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock worth $107,000 after acquiring an additional 82,030 shares during the period. UBS Group AG increased its position in Synthetic Biologics by 10.3% during the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock worth $135,000 after acquiring an additional 20,038 shares during the period. Bank of New York Mellon Corp increased its position in Synthetic Biologics by 3.1% during the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock worth $166,000 after acquiring an additional 7,962 shares during the period. Finally, LMR Partners LLP bought a new position in Synthetic Biologics during the second quarter worth about $194,000.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.